Unleashing the therapeutic potential of human kallikrein-related serine proteases

Authors:

Abstract
Tissue kallikreins (KLKs) constitute a family of 15 secreted serine proteases that are encoded by the largest protease gene cluster in the human genome. KLKs were traditionally known for their clinical applicability as cancer markers — for instance, KLK3 (also known as prostate-specific antigen) is a marker for prostate cancer. The field of KLK research has recently blossomed with the development of KLK-knockout models and the elucidation of the 3D structures of several KLKs. Novel pathophysiological roles for these proteases have recently been assigned in various tissues, such as the airway, cardiovascular system, tooth, skin and brain tissues. The promise of KLKs as therapeutic targets in various pathologies — including skin diseases, hereditary angioedema, neurodegeneration, inflammation and cancer — is emerging. Systematic efforts for the development of the first generation of KLK-based inhibitors as candidate therapeutics have already been initiated.

This publication has 226 references indexed in Scilit: